Clinical Practice Session
Should Disease Names Change to Reflect Genotype, Pathology, or Phenotype, and What Do Patients Think?
November 05, 2022 | 02:00 PM - 04:00 PM
Location: W320 Chapin, Orange County Convention Center, West Building
Session Description
This session reviews the issues around disease naming. Discussions include how changing the approach to names can reflect improved understanding of clinical phenotypes based on genetic, pathology, and other descriptors.
Support is provided by an educational grant from Travere Therapeutics, Inc.
Learning Objective(s)
- Explain the limitations of current disease naming
- Describe reasons to change naming methods, using FSGS as an example
- Specify alternatives to the use of eponymous and pathological terms for disease naming
Learning Pathway(s)
- Glomerular Diseases
- Genetic Diseases and Development
Moderators
- Rasheed A. Gbadegesin, MBBS, MD, FASN
- Catherine Quinlan, MD
Presentations
- Defining the Molecular Basis of Glomerular Disease
02:00 PM - 02:30 PM
Matthias Kretzler, MD
- Change the Name: Genetics-Focused Naming
02:30 PM - 03:00 PM
Alicia B Byrne, PhD
- Retain the Name: Pathology-Focused Naming
03:00 PM - 03:30 PM
Astrid Weins, MD, PhD, FASN
- Patient Perspective: Implications of Naming for Alport Syndrome
03:30 PM - 04:00 PM
Susie Gear
